Obesity and response to IBD treatment

Obesity has been identified as a significant factor influencing the response to treatment in patients with inflammatory bowel disease (IBD). A large registry-based study from the Initiative on Crohn and Colitis evaluated 1,066 patients initiating various therapies, including thiopurines with allopurinol, vedolizumab, ustekinumab, ozanimod, filgotinib, and tofacitinib. These patients were categorized into three groups based on their body mass index (BMI): normal weight (<25), overweight (25–29.9), and obesity (≥30). The primary outcome assessed was steroid-free clinical remission at week 24, defined using disease-specific activity indices.

### Key Findings:

1. **Reduced Remission in Obese Patients**:

• Patients with obesity had significantly lower rates of steroid-free clinical remission at week 24 compared to those with normal weight (35.3% vs. 48.6%).
• Obesity was independently associated with reduced odds of achieving remission, with an adjusted odds ratio of 0.537 (P = .005).

2. **Overweight Patients Showed Temporary Benefit**:

• Overweight patients demonstrated higher odds of achieving remission at week 12. However, this benefit did not persist at later time points.

3. **Long-term Outcomes**:

• By week 52, remission rates were comparable across all BMI categories, suggesting that the impact of BMI on treatment response may be more pronounced in the early phases of treatment.
• Treatment discontinuation rates did not differ significantly across BMI groups at any follow-up interval.

### Potential Mechanisms:

The reduced efficacy of IBD treatment in obese patients may be attributed to several factors:

• **Altered Drug Pharmacokinetics**: Obesity can affect drug absorption, distribution, metabolism, and elimination, potentially reducing the effectiveness of therapies.
• **Increased Systemic Inflammation**: Obesity is associated with a pro-inflammatory state, which may exacerbate IBD symptoms and hinder treatment response.
• **Microbiome-Related Mechanisms**: Obesity can alter gut microbiota composition, which may interact with IBD pathophysiology and treatment efficacy.

### Clinical Implications:

1. **Addressing Weight in IBD Management**:

• These findings highlight the importance of addressing obesity as part of IBD management.
• Nutritional counseling and lifestyle interventions should be incorporated to optimize both general health and therapeutic outcomes for obese IBD patients.

2. **Personalized Treatment Strategies**:

• Clinicians should consider the potential impact of obesity when selecting and monitoring IBD therapies.
• Further research is needed to explore whether specific treatments or dosing adjustments could mitigate the impact of obesity on treatment response.

In summary, obesity appears to hinder early treatment efficacy in IBD, likely due to a combination of biological and pharmacological factors. While remission rates eventually equalize across BMI categories by week 52, addressing obesity through integrated care approaches may enhance early treatment outcomes and overall disease management.